Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial.
暂无分享，去创建一个
S. Heiland | M. J. van den Bent | M. Weller | T. Gorlia | A. von Deimling | W. Wick | Klaus Maier-Hein | F. Isensee | P. Kickingereder | U. Neuberger | A. Wick | M. Bendszus | F. Sahm | M. Plattén | Irada Pflüger | G. Brugnara | M. Nowosielski | Marianne Schell | T. Kessler | M. Foltyn | Fabian Isensee